论文部分内容阅读
11例难治性多发性骨髓瘤(R-MM),男7例,女4例,中位数年龄56岁,IgG型7例,IgA型1例,轻链型3例。从诊断至本方案治疗前的病程平均25.1个月,曾接受M_2、MOPP、COMAP、COMP、ABMOP和COPM+VP16方案治疗5～25个疗程治疗无效,病情进行性加重。改良的VAD方案:长春新硷(V)0.5mg/d,阿霉素(A)10mg/d,分别溶于生理盐水或5％葡萄糖液250～500ml中静滴2～4小时,地塞米松10～19.5mg/日分次口服,三种药物连用4天,间歇4～7天
11 cases of refractory multiple myeloma (R-MM), 7 males and 4 females, with a median age of 56 years, 7 cases of IgG, 1 case of IgA and 3 cases of light chain. From the diagnosis to the program before the course of treatment an average of 25.1 months, who have received M_2, MOPP, COMAP, COMP, ABMOP and COPM + VP16 regimen of 5 to 25 courses of treatment ineffective, progressive aggravation. Modified VAD program: vincristine (V) 0.5mg / d, doxorubicin (A) 10mg / d, were dissolved in saline or 5% glucose solution 250 ~ 500ml intravenous infusion of 2 to 4 hours, dexamethasone 10 ~ 19.5mg / day oral administration, three drugs for 4 days, intermittent 4 to 7 days